Fig. 2: Clinical measure outcomes. | Nature Medicine

Fig. 2: Clinical measure outcomes.

From: Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study

Fig. 2

a, MADRS total scores at preinfusion and at day 1 postinfusion. The thick lines represent the mean values for each condition, with individual data points connected by thinner lines. b, Change in MADRS scores from preinfusion to day 1 postinfusion. c, Change in QIDS–SR scores from preinfusion to day 1 postinfusion. d, Change in M3VAS scores from preinfusion to day 1 postinfusion e, Change in SHAPS scores from preinfusion to day 1 postinfusion. f, Change in TEPS-A scores from preinfusion to day 1 postinfusion. g, Change in TEPS-C scores from preinfusion to day 1 postinfusion. Note an increase in TEPS-A and TEPS-C scores indicates a reduction in anhedonia symptoms. Box plot elements: box spans the IQR (25th–75th percentile), central line is the median (50th percentile), + marks the mean, whiskers extend to the lowest and highest values within 1.5 × IQR of the box and values beyond that range are shown individually. Each plot shows data from n = 26 participants who completed the crossover.

Back to article page